SPARK NS today announced the five projects that will receive up to $10 million to advance academic discoveries in Parkinson’s Disease from the lab to the clinic.
The projects were selected to participate in the SPARK NS 2024 Parkinson’s Disease Translational Research Program, an immersive two-year program designed to help academic research teams improve the odds their promising therapeutics will make it to market and benefit patients.
Said Daria Mochly-Rosen, PhD,?a Board Director and Chief Scientific and Education Advisor of SPARK NS, “Funding is essential, but it’s not enough. SPARK NS programs provide comprehensive resources and collaborative experiences that prepare academic researchers for the challenging process of drug development.”
Stephen Kargotich, PhD, MBA, LLB, Executive Director of SPARK NS, said of the projects,?“These are stellar examples of the work being done in the Parkinson’s disease research community. SPARK NS plans to launch a new program each year to ensure the translation of more academic discoveries into therapies that improve the quality of life for the millions of people around the world with Parkinson’s and other neurological disorders.”
The projects announced today are participating in our 2024 program, which is already underway. SPARK NS is in the process of reviewing applications submitted for our 2025 program and will notify finalists on August 23, 2024. We plan to issue a Call for Proposals for our 2026 program in April 2025.
For information on the five projects and their principal investigators, visit the SPARK NS website here: https://lnkd.in/g54rDPqd?
To view our press release, go click here: https://lnkd.in/gkCmEZii
The photo included in this post is of the principal Investigators for the five projects. From left to right, they are Gary W. Miller PhD, Columbia University; David Sulzer, PhD, Columbia University; Matthew D. Disney, PhD, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology (University of Florida); Alice S. Chen-Plotkin, MD, University of Pennsylvania; and James H. Hurley, PhD, University of California, Berkeley.